Loading…

Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update

Pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus infection is proved to be effective and has been implemented worldwide. This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. Th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of microbiology, immunology and infection immunology and infection, 2020-02, Vol.53 (1), p.1-10
Main Authors: Yen-Hao Chu, Isaac, Wen-Wei Ku, Stephane, Li, Chia-Wen, Toh, Han Siong, Yang, Chia-Jui, Wu, Kuan-Sheng, Wu, Huei-Jiuan, Chen, Shu-Sheng, Kuo, Jiann-Horng, Lin, Hsi-Hsun, Ko, Nai-Ying
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c466t-92a7d366722780c706cb6171aa188f45a5324c64a3b9253fb5bd63b206bd8b13
cites cdi_FETCH-LOGICAL-c466t-92a7d366722780c706cb6171aa188f45a5324c64a3b9253fb5bd63b206bd8b13
container_end_page 10
container_issue 1
container_start_page 1
container_title Journal of microbiology, immunology and infection
container_volume 53
creator Yen-Hao Chu, Isaac
Wen-Wei Ku, Stephane
Li, Chia-Wen
Toh, Han Siong
Yang, Chia-Jui
Wu, Kuan-Sheng
Wu, Huei-Jiuan
Chen, Shu-Sheng
Kuo, Jiann-Horng
Lin, Hsi-Hsun
Ko, Nai-Ying
description Pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus infection is proved to be effective and has been implemented worldwide. This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. The Taiwan PrEP guideline writing group searched randomized controlled trials and guidelines published before October 2017 through Medline/PubMed, Cochrane Database, Embase and ClinicalTrials.gov database. Keywords included pre(-)exposure prophylaxis, PrEP, Truvada, tenofovir, HIV, and AIDS. Each selected article was assessed by two authors using the Grading of Recommendations Assessment, Development and Evaluation. External reviewers were invited to independently evaluate the revised manuscript per the Appraisal of Guidelines for Research and Evaluation II. Before publication, a public consultation was held to reach consensus on the updated guideline among providers, civil society, and Taiwan Centers for Disease Control. Four systematic reviews and 28 original articles were reviewed by Taiwan PrEP writing group. The second version of the Taiwan PrEP guideline was released in March 2018. We recommended daily PrEP use for the following populations: strong recommendation and high quality of evidence for men who have sex with men (MSM) and transgender women (TGW), as well as heterosexual serodiscordant couples; weak recommendation and high quality of evidence for people who inject drugs, while weak recommendation and moderate quality of evidence for at-risk heterosexual men and women. There is high-quality evidence for event-driven PrEP in MSM and likely TGW, and we additionally recognized these key populations could benefit from such dosing regimen.
doi_str_mv 10.1016/j.jmii.2019.09.003
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7c24a2861a3f4180b39152ece0d34fa3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1684118219301434</els_id><doaj_id>oai_doaj_org_article_7c24a2861a3f4180b39152ece0d34fa3</doaj_id><sourcerecordid>2307148954</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-92a7d366722780c706cb6171aa188f45a5324c64a3b9253fb5bd63b206bd8b13</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EoqXwAhxQjlyy-F8cR-KCKqArVeKy4mqN7UlxlI2DnZT2xjvwhjwJDlt6RBpp7NE3v_H4I-Q1oztGmXo37IZjCDtOWbejJah4Qs5Z1zV1x4R4Ws5Ky5oxzc_Ii5wHSqXgjXpOzgRTXFPdnpPDAcIPmKqbNXgcw4RVnKqYYKzmhDXezTGvCcslzt_uR7gLuepjqq72XzfBLU5LKA2_f_6qyjN0tc4eFnxJnvUwZnz1kC_I4dPHw-VVff3l8_7yw3XtpFJL3XFovVCq5bzV1LVUOatYywCY1r1soBFcOiVB2I43oreN9UpYTpX12jJxQfYnrI8wmDmFI6R7EyGYv4WYbgykJbgRTeu4BK4VA9FLpqkVHWs4OqReyB5EYb09scqm31fMizmG7HAcYcK4ZsMFbZnUXSOLlJ-kLsWcE_aPoxk1mzFmMJsxZjPG0BJ047954K_2iP6x5Z8TRfD-JMDyYbcBk8ku4OTQh4RuKSuF__H_AMM2nb4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2307148954</pqid></control><display><type>article</type><title>Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><creator>Yen-Hao Chu, Isaac ; Wen-Wei Ku, Stephane ; Li, Chia-Wen ; Toh, Han Siong ; Yang, Chia-Jui ; Wu, Kuan-Sheng ; Wu, Huei-Jiuan ; Chen, Shu-Sheng ; Kuo, Jiann-Horng ; Lin, Hsi-Hsun ; Ko, Nai-Ying</creator><creatorcontrib>Yen-Hao Chu, Isaac ; Wen-Wei Ku, Stephane ; Li, Chia-Wen ; Toh, Han Siong ; Yang, Chia-Jui ; Wu, Kuan-Sheng ; Wu, Huei-Jiuan ; Chen, Shu-Sheng ; Kuo, Jiann-Horng ; Lin, Hsi-Hsun ; Ko, Nai-Ying</creatorcontrib><description>Pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus infection is proved to be effective and has been implemented worldwide. This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. The Taiwan PrEP guideline writing group searched randomized controlled trials and guidelines published before October 2017 through Medline/PubMed, Cochrane Database, Embase and ClinicalTrials.gov database. Keywords included pre(-)exposure prophylaxis, PrEP, Truvada, tenofovir, HIV, and AIDS. Each selected article was assessed by two authors using the Grading of Recommendations Assessment, Development and Evaluation. External reviewers were invited to independently evaluate the revised manuscript per the Appraisal of Guidelines for Research and Evaluation II. Before publication, a public consultation was held to reach consensus on the updated guideline among providers, civil society, and Taiwan Centers for Disease Control. Four systematic reviews and 28 original articles were reviewed by Taiwan PrEP writing group. The second version of the Taiwan PrEP guideline was released in March 2018. We recommended daily PrEP use for the following populations: strong recommendation and high quality of evidence for men who have sex with men (MSM) and transgender women (TGW), as well as heterosexual serodiscordant couples; weak recommendation and high quality of evidence for people who inject drugs, while weak recommendation and moderate quality of evidence for at-risk heterosexual men and women. There is high-quality evidence for event-driven PrEP in MSM and likely TGW, and we additionally recognized these key populations could benefit from such dosing regimen.</description><identifier>ISSN: 1684-1182</identifier><identifier>EISSN: 1995-9133</identifier><identifier>DOI: 10.1016/j.jmii.2019.09.003</identifier><identifier>PMID: 31628087</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Human immunodeficiency virus ; Pre-exposure prophylaxis ; PrEP ; Taiwan</subject><ispartof>Journal of microbiology, immunology and infection, 2020-02, Vol.53 (1), p.1-10</ispartof><rights>2019</rights><rights>Copyright © 2019. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-92a7d366722780c706cb6171aa188f45a5324c64a3b9253fb5bd63b206bd8b13</citedby><cites>FETCH-LOGICAL-c466t-92a7d366722780c706cb6171aa188f45a5324c64a3b9253fb5bd63b206bd8b13</cites><orcidid>0000-0002-3007-2537 ; 0000-0001-6645-1857</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31628087$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yen-Hao Chu, Isaac</creatorcontrib><creatorcontrib>Wen-Wei Ku, Stephane</creatorcontrib><creatorcontrib>Li, Chia-Wen</creatorcontrib><creatorcontrib>Toh, Han Siong</creatorcontrib><creatorcontrib>Yang, Chia-Jui</creatorcontrib><creatorcontrib>Wu, Kuan-Sheng</creatorcontrib><creatorcontrib>Wu, Huei-Jiuan</creatorcontrib><creatorcontrib>Chen, Shu-Sheng</creatorcontrib><creatorcontrib>Kuo, Jiann-Horng</creatorcontrib><creatorcontrib>Lin, Hsi-Hsun</creatorcontrib><creatorcontrib>Ko, Nai-Ying</creatorcontrib><title>Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update</title><title>Journal of microbiology, immunology and infection</title><addtitle>J Microbiol Immunol Infect</addtitle><description>Pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus infection is proved to be effective and has been implemented worldwide. This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. The Taiwan PrEP guideline writing group searched randomized controlled trials and guidelines published before October 2017 through Medline/PubMed, Cochrane Database, Embase and ClinicalTrials.gov database. Keywords included pre(-)exposure prophylaxis, PrEP, Truvada, tenofovir, HIV, and AIDS. Each selected article was assessed by two authors using the Grading of Recommendations Assessment, Development and Evaluation. External reviewers were invited to independently evaluate the revised manuscript per the Appraisal of Guidelines for Research and Evaluation II. Before publication, a public consultation was held to reach consensus on the updated guideline among providers, civil society, and Taiwan Centers for Disease Control. Four systematic reviews and 28 original articles were reviewed by Taiwan PrEP writing group. The second version of the Taiwan PrEP guideline was released in March 2018. We recommended daily PrEP use for the following populations: strong recommendation and high quality of evidence for men who have sex with men (MSM) and transgender women (TGW), as well as heterosexual serodiscordant couples; weak recommendation and high quality of evidence for people who inject drugs, while weak recommendation and moderate quality of evidence for at-risk heterosexual men and women. There is high-quality evidence for event-driven PrEP in MSM and likely TGW, and we additionally recognized these key populations could benefit from such dosing regimen.</description><subject>Human immunodeficiency virus</subject><subject>Pre-exposure prophylaxis</subject><subject>PrEP</subject><subject>Taiwan</subject><issn>1684-1182</issn><issn>1995-9133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kc9u1DAQxi0EoqXwAhxQjlyy-F8cR-KCKqArVeKy4mqN7UlxlI2DnZT2xjvwhjwJDlt6RBpp7NE3v_H4I-Q1oztGmXo37IZjCDtOWbejJah4Qs5Z1zV1x4R4Ws5Ky5oxzc_Ii5wHSqXgjXpOzgRTXFPdnpPDAcIPmKqbNXgcw4RVnKqYYKzmhDXezTGvCcslzt_uR7gLuepjqq72XzfBLU5LKA2_f_6qyjN0tc4eFnxJnvUwZnz1kC_I4dPHw-VVff3l8_7yw3XtpFJL3XFovVCq5bzV1LVUOatYywCY1r1soBFcOiVB2I43oreN9UpYTpX12jJxQfYnrI8wmDmFI6R7EyGYv4WYbgykJbgRTeu4BK4VA9FLpqkVHWs4OqReyB5EYb09scqm31fMizmG7HAcYcK4ZsMFbZnUXSOLlJ-kLsWcE_aPoxk1mzFmMJsxZjPG0BJ047954K_2iP6x5Z8TRfD-JMDyYbcBk8ku4OTQh4RuKSuF__H_AMM2nb4</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Yen-Hao Chu, Isaac</creator><creator>Wen-Wei Ku, Stephane</creator><creator>Li, Chia-Wen</creator><creator>Toh, Han Siong</creator><creator>Yang, Chia-Jui</creator><creator>Wu, Kuan-Sheng</creator><creator>Wu, Huei-Jiuan</creator><creator>Chen, Shu-Sheng</creator><creator>Kuo, Jiann-Horng</creator><creator>Lin, Hsi-Hsun</creator><creator>Ko, Nai-Ying</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3007-2537</orcidid><orcidid>https://orcid.org/0000-0001-6645-1857</orcidid></search><sort><creationdate>202002</creationdate><title>Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update</title><author>Yen-Hao Chu, Isaac ; Wen-Wei Ku, Stephane ; Li, Chia-Wen ; Toh, Han Siong ; Yang, Chia-Jui ; Wu, Kuan-Sheng ; Wu, Huei-Jiuan ; Chen, Shu-Sheng ; Kuo, Jiann-Horng ; Lin, Hsi-Hsun ; Ko, Nai-Ying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-92a7d366722780c706cb6171aa188f45a5324c64a3b9253fb5bd63b206bd8b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Human immunodeficiency virus</topic><topic>Pre-exposure prophylaxis</topic><topic>PrEP</topic><topic>Taiwan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yen-Hao Chu, Isaac</creatorcontrib><creatorcontrib>Wen-Wei Ku, Stephane</creatorcontrib><creatorcontrib>Li, Chia-Wen</creatorcontrib><creatorcontrib>Toh, Han Siong</creatorcontrib><creatorcontrib>Yang, Chia-Jui</creatorcontrib><creatorcontrib>Wu, Kuan-Sheng</creatorcontrib><creatorcontrib>Wu, Huei-Jiuan</creatorcontrib><creatorcontrib>Chen, Shu-Sheng</creatorcontrib><creatorcontrib>Kuo, Jiann-Horng</creatorcontrib><creatorcontrib>Lin, Hsi-Hsun</creatorcontrib><creatorcontrib>Ko, Nai-Ying</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal of microbiology, immunology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yen-Hao Chu, Isaac</au><au>Wen-Wei Ku, Stephane</au><au>Li, Chia-Wen</au><au>Toh, Han Siong</au><au>Yang, Chia-Jui</au><au>Wu, Kuan-Sheng</au><au>Wu, Huei-Jiuan</au><au>Chen, Shu-Sheng</au><au>Kuo, Jiann-Horng</au><au>Lin, Hsi-Hsun</au><au>Ko, Nai-Ying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update</atitle><jtitle>Journal of microbiology, immunology and infection</jtitle><addtitle>J Microbiol Immunol Infect</addtitle><date>2020-02</date><risdate>2020</risdate><volume>53</volume><issue>1</issue><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>1684-1182</issn><eissn>1995-9133</eissn><abstract>Pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus infection is proved to be effective and has been implemented worldwide. This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. The Taiwan PrEP guideline writing group searched randomized controlled trials and guidelines published before October 2017 through Medline/PubMed, Cochrane Database, Embase and ClinicalTrials.gov database. Keywords included pre(-)exposure prophylaxis, PrEP, Truvada, tenofovir, HIV, and AIDS. Each selected article was assessed by two authors using the Grading of Recommendations Assessment, Development and Evaluation. External reviewers were invited to independently evaluate the revised manuscript per the Appraisal of Guidelines for Research and Evaluation II. Before publication, a public consultation was held to reach consensus on the updated guideline among providers, civil society, and Taiwan Centers for Disease Control. Four systematic reviews and 28 original articles were reviewed by Taiwan PrEP writing group. The second version of the Taiwan PrEP guideline was released in March 2018. We recommended daily PrEP use for the following populations: strong recommendation and high quality of evidence for men who have sex with men (MSM) and transgender women (TGW), as well as heterosexual serodiscordant couples; weak recommendation and high quality of evidence for people who inject drugs, while weak recommendation and moderate quality of evidence for at-risk heterosexual men and women. There is high-quality evidence for event-driven PrEP in MSM and likely TGW, and we additionally recognized these key populations could benefit from such dosing regimen.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>31628087</pmid><doi>10.1016/j.jmii.2019.09.003</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3007-2537</orcidid><orcidid>https://orcid.org/0000-0001-6645-1857</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1684-1182
ispartof Journal of microbiology, immunology and infection, 2020-02, Vol.53 (1), p.1-10
issn 1684-1182
1995-9133
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7c24a2861a3f4180b39152ece0d34fa3
source BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS
subjects Human immunodeficiency virus
Pre-exposure prophylaxis
PrEP
Taiwan
title Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T10%3A39%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Taiwan%20guideline%20on%20oral%20pre-exposure%20prophylaxis%20for%20HIV%20prevention%20%E2%80%93%202018%20update&rft.jtitle=Journal%20of%20microbiology,%20immunology%20and%20infection&rft.au=Yen-Hao%20Chu,%20Isaac&rft.date=2020-02&rft.volume=53&rft.issue=1&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=1684-1182&rft.eissn=1995-9133&rft_id=info:doi/10.1016/j.jmii.2019.09.003&rft_dat=%3Cproquest_doaj_%3E2307148954%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c466t-92a7d366722780c706cb6171aa188f45a5324c64a3b9253fb5bd63b206bd8b13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2307148954&rft_id=info:pmid/31628087&rfr_iscdi=true